Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?
Open Access
- 30 October 2020
- journal article
- review article
- Published by Elsevier in Neurotherapeutics
- Vol. 17 (4) , 1539-1562
Abstract
No abstract availableKeywords
Funding Information
- Medical Research Council (G102328, MR/R015724/1)
- National Institute for Health Research (146281)
- Wellcome Trust (203151/Z/16/Z)
This publication has 199 references indexed in Scilit:
- The AAV Vector Toolkit: Poised at the Clinical CrossroadsMolecular Therapy, 2012
- Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s diseaseNature, 2011
- Interventional MRI-guided Putaminal Delivery of AAV2-GDNF for a Planned Clinical Trial in Parkinson's DiseaseMolecular Therapy, 2011
- Gene Therapy of Chronic Granulomatous Disease: The Engraftment DilemmaMolecular Therapy, 2011
- A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's DiseaseMolecular Therapy, 2010
- Real-time MR Imaging With Gadoteridol Predicts Distribution of Transgenes After Convection-enhanced Delivery of AAV2 VectorsMolecular Therapy, 2010
- Eight Years of Clinical Improvement in MPTP-Lesioned Primates After Gene Therapy With AAV2-hAADCMolecular Therapy, 2010
- Efficacy of Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2010
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisNew England Journal of Medicine, 2008